<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan Buter, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine T Steele, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin C Chung, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kate Elzinga, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy S Colwell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amalia Cochran, MD, FACS, FCCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drugs can be harmful when directly exposed to tissues, especially those classified as vesicants, which have the potential to cause severe tissue damage with lasting injury. "Extravasation" refers to the escape of a vesicant drug into the extravascular space; leakage of a nonvesicant drug is referred to as "infiltration" [<a href="#rid1">1,2</a>]. The drug can enter the extravascular space by leaking from the point where the catheter enters the vessel, from a point where a catheter has punctured through a vein, by causing direct damage to the vein, or from central venous access device malfunction. Although the most well-known vesicants are cytotoxic chemotherapy (antineoplastic) drugs  (<a class="graphic graphic_table graphicRef67517" href="/d/graphic/67517.html" rel="external">table 1</a>), many other noncytotoxic drugs also have the potential for local toxicity  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p>The clinical features and management of extravasation injury are reviewed. Venous irritation without leakage (phlebitis), and other cutaneous complications of infusion therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8195.html" rel="external">"Catheter-related upper extremity venous thrombosis in adults", section on 'Phlebitis'</a> and  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.) </p><p class="headingAnchor" id="H1594053423"><span class="h1">INCIDENCE AND RISK FACTORS</span></p><p class="headingAnchor" id="H4062641237"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The true incidence of extravasation injury is largely unknown because there are no central reporting mechanisms, with many incidents going unreported [<a href="#rid3">3-5</a>]. The estimated prevalence of chemotherapy extravasation through a peripheral intravenous line is 0.1 to 6 percent, and from 0.3 to 4.7 percent when administered through a central venous access device (CVAD) [<a href="#rid6">6</a>]. For noncytotoxic medications, the incidence also varies [<a href="#rid3">3,7-10</a>]. One review estimated that extravasation of noncytotoxic medications occurred in &lt;1 to 6 percent of adults [<a href="#rid8">8</a>]. </p><p>With an increasing awareness of the risks of extravasation, the frequency of chemotherapy-related extravasation appears to have fallen. Data from MD Anderson Cancer Center indicate that the rate of serious extravasation injury (as determined by referral patterns to a plastic surgery clinic) declined from 0.1 to 0.01 percent over a 15-year period based on individual doses of chemotherapy administered [<a href="#rid11">11</a>]. However, this series only included patients referred to plastic surgery not all extravasations, and as such, this rate underestimates the true incidence of chemotherapy extravasation injury. </p><p>Infusion of cytotoxic antineoplastic agents is frequently done through a CVAD to minimize venous injury and the consequences of peripheral extravasation. Although the risk of extravasation through a CVAD is lower compared with extravasation at peripheral sites, it is not zero [<a href="#rid5">5,12-15</a>]. Extravasation in this setting might be due to injection technique (eg, access needle misplaced) or device failure (eg, disconnected catheter) [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center report of 376 patients receiving high-dose chemotherapy and peripheral blood stem cell transplantation through a totally implanted port device over a five-year period, there was one case of extravasation (0.26 percent) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another series noted three extravasations in 225 CVADs (various tunneled catheters, implanted ports) implanted in 217 patients over an 11-year period (1.3 percent) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third report noted 15 cases of drug extravasation among 815 consecutive cancer patients (1.8 percent) who received chemotherapy with a totally implanted port over a one-year period, not all of whom were receiving vesicants [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H2293622028"><span class="h2">Risk factors</span></p><p class="headingAnchor" id="H348453783"><span class="h3">Peripheral access sites</span><span class="headingEndMark"> — </span>Risk factors for extravasation injury from a peripheral vein include the following [<a href="#rid16">16-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Small and/or fragile veins. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-related or medical comorbidities that alter the integrity of the skin and subcutaneous tissue or impair tissue perfusion (eg, peripheral artery disease, diabetes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased body mass index &gt;30, which may increase the difficulty of establishing intravenous access or contribute to dislodgment of a catheter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficult venous access or limited vein ability due to prior venous access, prior chemotherapy, or other irritating drugs (eg, <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient movement, particularly if the intravenous catheter is placed near a joint (eg, antecubital fossa, hand/wrist, foot/ankle).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive or neurologic deficits (eg, peripheral neuropathy), or other conditions that impair a patient's ability to sense or react to pain at the site of drug administration. These can increase the risk of extravasation, even in the setting of continuous supervision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged infusion duration (&gt;24 hours).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bolus infusion (eg, power injectors for radiocontrast media). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of winged steel infusion devices (ie, "butterfly needles").</p><p></p><p class="headingAnchor" id="H2611159958"><span class="h3">Central access sites</span><span class="headingEndMark"> — </span>Risk factors for extravasation from a central venous access site include the following [<a href="#rid14">14,18,20-23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty encountered during insertion of the device, such as probing or inability to advance the guidewire or catheter. With improper technique, catheters can also become inadvertently damaged before or during insertion, or malpositioned.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catheter migration from the vein into the tissue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long dwell time (six months or longer); soft catheter materials are prone to weakening and "pinch off" syndrome, which occurs when the catheter is compressed between the clavicle and the first or second rib. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a fibrin sheath or thrombus at the catheter tip, which may cause vesicant chemotherapy to backtrack along the catheter and leak from the vein at the access site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A deeply implanted port device increases the risk that the length of an access needle will not be sufficiently long to be correctly positioned into the port septum, or that patient movement will cause "rocking" of the needle within the port septum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous stenosis or thrombosis located more central than the catheter tip. </p><p></p><p class="headingAnchor" id="H1840272676"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>The best approach to extravasation injury is prevention [<a href="#rid22">22</a>]. Guidelines for preventing extravasation are available from the Infusion Nurses Society [<a href="#rid18">18</a>], Oncology Nursing Society (ONS), and the European Oncology Nursing Society (EONS) [<a href="#rid21">21,24</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral intravenous devices</strong> – Appropriate peripheral venous site selection (large vein away from areas of sclerosis or scar) and proper device placement and securement can minimize the risk of extravasation injury. (See  <a class="medical medical_review" href="/d/html/13824.html" rel="external">"Peripheral venous access in adults", section on 'Site selection'</a> and  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices", section on 'Dressing and securement'</a>.)</p><p></p><p class="bulletIndent1">Vesicant agents should not be infused through veins in the antecubital fossa, wrist, or dorsum of the hand because extravasation in these regions can cause serious long-term morbidity. For irritants, we try to avoid these sites as well, if possible. The butterfly needle or plastic cannula should be secured to the skin with tape and a transparent dressing used to cover the skin entry site to allow for direct observation of the site. Just prior to starting a drug infusion, the patency of the intravenous line should be demonstrated (eg, flush with 5 to 10 mL of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or a 5 percent dextrose solution) and good blood return verified. </p><p></p><p class="bulletIndent1">During the infusion, patients should be closely monitored for pain (often described as mild to severe burning radiating along the vein), and the site should be inspected for erythema or swelling [<a href="#rid19">19</a>]. Patients should also be instructed to notify a clinician immediately if they experience any pain, leaking, or other changes in sensation at the infusion site. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central venous devices</strong> – Using a central venous catheter for infusion of vesicant drugs provides reliable venous access, high flow rates, and rapid drug dilution. However, extravasation can occur [<a href="#rid25">25</a>]. As with peripheral venous access devices, appropriate site selection and proper device placement and securement can minimize the risk of extravasation injury. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults"</a> and  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices", section on 'Dressing and securement'</a>.)</p><p></p><p class="bulletIndent1">Following CVAD placement, the position of the catheter should be confirmed prior to drug administration. In addition, if there are any complaints of pain at the port/catheter site, reports of chest pain or dyspnea (even without soft tissue swelling), or inability to draw blood or flush the catheter, the position of the catheter should be assessed prior to continuing with the infusion. (See <a class="local">'Risk factors'</a> above and  <a class="medical medical_review" href="/d/html/8194.html" rel="external">"Central venous access in adults: General principles", section on 'Confirming catheter tip position'</a>.)</p><p></p><p class="headingAnchor" id="H3114845790"><span class="h1">MECHANISMS OF INJURY</span><span class="headingEndMark"> — </span>Extravasation injury can be due to the direct effects of a drug (eg, cytotoxicity that prevents cell replication or growth), or to other pharmacologic or physiochemical properties of the drug  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). Many other infusions may have irritant properties that can also cause tissue injury. </p><p>Extravasation injury is best described for cytotoxic (antineoplastic) agents [<a href="#rid18">18,22,24</a>], but a number of noncytotoxic drugs (eg, vasopressors, radiographic contrast agents) have been documented to cause tissue necrosis and thereby act as vesicants [<a href="#rid7">7,16,26-31</a>]. </p><p class="headingAnchor" id="H921144674"><span class="h2">Cytotoxicity</span><span class="headingEndMark"> — </span>Cytotoxicity refers to the direct effect of a drug. Based on the severity of local toxicity, cytotoxic chemotherapy drugs have been historically classified as vesicants or irritants [<a href="#rid6">6,18,24,32,33</a>]. However, there is no universally accepted scoring system for classifying a medication as an irritant or vesicant.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritants</strong> – Irritants cause inflammation (warmth, erythema, tenderness) at the administration site and along the vein, but they rarely result in direct toxicity to the tissue (ie, necrosis). Drugs classified as irritants may be administered through a CVAD or peripheral venous access device. However, if the risk for injury is substantial in the setting of an extravasation, a CVAD is preferred. Some irritants can cause tissue necrosis if large volumes of concentrated solutions have extravasated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vesicants</strong> – Extravasation of a vesicant drug has the potential to cause tissue necrosis (blistering, sloughing of tissue, and varying degrees of deep tissue damage), resulting in a more severe and/or lasting injury than is typically seen with irritants because they are inherently toxic. </p><p></p><p>In addition to a designation as an irritant or vesicant  (<a class="graphic graphic_table graphicRef67517" href="/d/graphic/67517.html" rel="external">table 1</a>), chemotherapeutic vesicants are subclassified as non-DNA binding and DNA binding. Non-DNA-binding agents are metabolized and neutralized in the tissues, whereas DNA-binding drugs (eg, anthracyclines such as <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>) set up a continuous cycle of tissue damage that is mediated by cellular DNA, resulting in more extensive injuries [<a href="#rid33">33</a>]. </p><p>Anthracyclines are among the most important cytotoxic agents that cause extravasation injury because of their widespread use in various chemotherapy regimens and their tendency to produce severe tissue necrosis. Because of the risk for serious injury if extravasation occurs, any vesicant drug, particularly if it is administered as an infusion rather than a bolus, should preferably be administered via a CVAD rather than a peripheral venous access device [<a href="#rid18">18,24</a>]. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Factors influencing catheter selection'</a>.) </p><p>For some cytotoxic chemotherapy agents, the distinction between vesicant and irritant is not absolute. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>There are reports of severe tissue injury from extravasation of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid34">34,35</a>], although another series of 11 patients showed no tissue destruction [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most injection site reactions following extravasation of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> consist of redness, tenderness, and swelling, but there are case reports that document necrosis and skin exfoliation [<a href="#rid37">37-40</a>]. However, only rarely are long-term sequelae reported, such as ulceration requiring surgical intervention [<a href="#rid41">41</a>]. In a compilation of 35 reported cases of paclitaxel extravasation, only three developed ulceration, two requiring skin closure [<a href="#rid37">37</a>]. Although most references classify paclitaxel as an irritant drug, the Oncology Nursing Society (ONS) and Multinational Association of Supportive Care in Cancer (MASCC) classify it as a vesicant [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">Mitoxantrone</a>, usually classified as an irritant, has been reported to cause skin necrosis requiring surgical debridement and skin grafting [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">Ado-trastuzumab emtansine</a>, an antibody-drug conjugate that consists of the antihuman epidermal growth factor receptor 2 monoclonal antibody <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> conjugated to emtansine, a highly cytotoxic antimicrotubule agent, has been classified as an irritant; however, a single case report of skin necrosis following subcutaneous extravasation has been reported [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a>, a nectin-4-directed antibody and microtubule inhibitor drug conjugate that is approved for advanced refractory urothelial cancer, has been associated with skin and soft tissue reactions secondary to extravasation (1.3 percent of 310 treated patients) [<a href="#rid45">45</a>]. Some of the extravasation reactions were associated with secondary cellulitis, bullae, or exfoliation. However, whether this drug causes deep tissue damage is uncertain.</p><p></p><p>In such cases, the extent of tissue injury may be a function of the amount of drug extravasated.</p><p class="headingAnchor" id="H1481107686"><span class="h2">Other drug properties</span><span class="headingEndMark"> — </span>In addition to the cytotoxic effects of a specific drug , the properties of the drug solution (ie, osmolarity, pH), drug concentration, presence of diluents, and volume of escaping drug also contribute to the potential for injury  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). Infusates with pH values that are very low (&lt;5.5 pH) or very high (&gt;8.5 pH) are particularly harmful to tissues [<a href="#rid8">8,33</a>]. Similarly, infusion of hypo- or hyperosmolar agents (&lt;281 or &gt;289 mOsmol/L, respectively) can lead to significant tissue damage [<a href="#rid33">33</a>]. In clinical practice, injuries from hyperosmolar agents are more common (eg, hyperosmolar radiographic contrast, some <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> solutions). Such agents should be administered through a CVAD rather than peripherally. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Factors influencing catheter selection'</a>.)</p><p>Other mechanisms may also be responsible for extravasation injury. The presence of drug diluents used in the formulation of some medications (eg, benzyl alcohol, polyethylene glycol, propylene glycol) may also contribute. As an example, propylene glycol used as a solvent in some parenteral medications (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>) may contribute to tissue injury by inducing inflammation or changes in physical properties. </p><p>For some agents, the mechanism of injury is unclear. As an example, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a> has been associated with thrombophlebitis, necrosis, and blistering but how extravasation injury occurs is unknown.</p><p class="headingAnchor" id="H2716532142"><span class="h2">Mechanical effects</span><span class="headingEndMark"> — </span>In addition to the chemical and other drug properties, tissue injury can also be caused by the mechanical effects of the fluid escaping from vasculature [<a href="#rid8">8</a>]. The necessary volume to result in an adverse mechanical effect depends on the potential space available and the structure surrounding the vein. </p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H979425345"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Early symptoms and signs of extravasation injury are often subtle. They usually appear immediately after the extravasation, but can be delayed for days to weeks [<a href="#rid2">2,7,18,24,46</a>]. Initially, there is local burning or tingling at the infusion site, mild erythema, pruritus, and swelling. Within two to three days, increased erythema, pain, brawny discoloration, induration, dry desquamation  (<a class="graphic graphic_picture graphicRef109446" href="/d/graphic/109446.html" rel="external">picture 1</a>), and/or blistering may appear [<a href="#rid47">47</a>]. With a small volume of extravasation, symptoms may disappear over several weeks. With larger volumes, necrosis, eschar formation, and ulceration with raised, red, painful edges and a yellow necrotic base may develop over a few days to several weeks. The National Cancer Institute Common Terminology Criteria for Adverse Events has provided a clinical classification of extravasation injury  (<a class="graphic graphic_table graphicRef91248" href="/d/graphic/91248.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Escape of an irritant drug causes a local inflammatory reaction, with aching, burning, tightness, pain, and phlebitis at the needle insertion site or along the vein. Clinical signs include warmth, erythema, and tenderness in the area, without tissue sloughing or necrosis. Symptoms are usually of short duration with no long-lasting sequelae provided the volume is limited. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Escape of a vesicant can produce local tissue necrosis both within and outside the venous system [<a href="#rid33">33</a>]. This may result in full-thickness loss of the skin and, if severe, underlying structures. Vesicant-induced ulcerations lack granulation tissue and have little epithelial ingrowth. Although very small ulcers typically heal gradually, larger lesions tend to persist, gradually expanding over time. If left untreated, underlying tendons, nerves, and vessels may be destroyed, potentially leading to nerve compression syndromes, permanent joint stiffness, contractures, and neurologic dysfunction [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a drug escapes from a central venous access device (CVAD), the solution may accumulate in the subcutaneous tissues near the catheter exit site, leading predominantly to pain in the neck, anterior chest, or groin. However, the extravasated solution can also accumulate in the mediastinum or pleural space. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There have been reports of an extravasation recall phenomenon, where previous sites of extravasation of a vesicant drug become inflamed upon re-exposure to the same drug administered at a remote intravenous site. This phenomenon has been reported with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid48">48-50</a>], <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid51">51,52</a>], <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid53">53,54</a>], and <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> [<a href="#rid55">55</a>]. </p><p></p><p class="headingAnchor" id="H4098496213"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Peripheral extravasation injuries are best assessed and followed with clinical examination. In select cases, imaging (eg, ultrasound) can help quantify the volume and determine the peripheral margins of the extravasation.</p><p>For patients with suspected extravasation from a CVAD, the infusion should be stopped, and a chest radiograph should be obtained to evaluate the position of the tip of the catheter and to verify the integrity of the components. (See <a class="local">'Initial measures'</a> below.)</p><p>If plain radiography is suspicious for extravascular catheter migration, a computed tomography (CT) scan should be obtained. Apparent extravascular catheter tip migration requires immediate attention. (See <a class="local">'Surgical referral'</a> below and <a class="local">'Catheter management'</a> below.)</p><p>The extent of CVAD extravasation can be initially evaluated with cross-sectional imaging, typically with a CT scan of the neck/chest (internal jugular, subclavian venous access) or abdomen/pelvis (femoral venous access). An alternative is ultrasound, which also assesses the underlying vein (eg, extrinsic compression causing deep vein thrombosis). During the follow-up period, B-mode ultrasound can be used to follow for resolution of the fluid collection or development of complications (eg, subcutaneous abscess). If the catheter tip is properly positioned and there are no large fluid collections, fluoroscopy with administration of dilute intravenous contrast can help to localize any other causes of catheter malfunction. </p><p>All patients with suspected mediastinal extravasation from a CVAD should undergo an initial CT scan of the chest; follow-up imaging can be performed with standard chest radiographs. </p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT OVERVIEW</span><span class="headingEndMark"> — </span>In general, the goals of treatment of suspected extravasation injury are to prevent local as well as any systemic effects of extravasated agent. Initial measures focus on limiting the amount of the agent within the tissues, thereby reducing the mechanical effects but also the amount of the agent that can be absorbed systemically. Application of cold or heat and selective use of antidotes aims to minimize tissue loss.</p><p>An overview of our recommended approach to the management of cytotoxic extravasations (including the use of specific antidotes), which follows the general guidelines of the Oncology Nursing Society (ONS) and European Oncology Nursing Society (EONS) [<a href="#rid24">24</a>], is summarized in the table  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>). Similarly, an approach to the management of extravasation of noncytotoxic agents, which is based upon collective reviews, is summarized in the table  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>) [<a href="#rid7">7,8,18,56</a>]. Specific treatment for selected agents is discussed below. (See <a class="local">'Local treatment of selected extravasations'</a> below.)</p><p class="headingAnchor" id="H3201964854"><span class="h2">Initial measures</span><span class="headingEndMark"> — </span>When extravasation of an irritant or vesicant drug is suspected (peripheral or central venous access), the following initial management is recommended [<a href="#rid8">8,18,24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the infusion immediately. Do <strong>not</strong> flush the line and avoid applying pressure to the extravasated site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For peripheral sites (peripheral cannula, midline) and peripherally inserted central catheters, elevate the affected extremity, which may help reduce edema and pain [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do <strong>not</strong> remove the catheter/needle immediately. Instead, it should be left in place to attempt to aspirate fluid from the extravasated area and to facilitate the administration of an antidote to the local area, if appropriate. Whether aspiration is effective with a central venous access catheter is uncertain, but this can be tried. (See <a class="local">'Selective use of antidotes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an antidote will not be injected into the extravasation site, the peripheral catheter/needle can be removed after attempting aspiration of the subcutaneous tissues. The handling of central venous access devices (CVADs) is discussed below. (See <a class="local">'Local tissue injury'</a> below.)</p><p></p><p>For extravasations into the chest, initial conservative management is reasonable, provided there is no evidence of mediastinitis or empyema [<a href="#rid15">15,58-60</a>]. While extravasation injuries can cause severe tissue damage and necrosis of the skin and subcutaneous tissue, the extent of damage to mediastinal or pulmonary structures tends to be more limited. The serous layers of the mediastinum likely protect against damage from extravasation [<a href="#rid15">15</a>]. Conservative management that includes antibiotics, analgesics, and pleural drainage (ie, thoracostomy tube) is typically sufficient. Antipyretics should be considered since fever is reported in 80 percent of chest extravasation cases [<a href="#rid15">15</a>]. If imaging demonstrates significant fluid collection, drainage or more extensive procedures may rarely be necessary [<a href="#rid58">58,59</a>]. (See <a class="local">'Imaging'</a> above and <a class="local">'Mediastinal extravasation'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Application of cold or heat</span><span class="headingEndMark"> — </span>Whether cold or heat is appropriate depends on the nature of the extravasated drug (cytotoxic  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>), noncytotoxic  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>)) and mechanism of injury.</p><p class="bulletIndent1"><span class="glyph">●</span>Cold compresses reduce pain and inflammation, and vasoconstriction localizes the vesicant potentially facilitating administration of an antidote [<a href="#rid61">61-63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Application of warmth causes vasodilation and may facilitate dispersion and absorption. Warmth is often used in conjunction with <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> to facilitate its mechanism of action.</p><p></p><p>When used, dry cold or warm compresses should be applied to the affected area for 20 minutes once every four to six hours for one to two days after removal of the needle or catheter. If compresses provide comfort and symptomatic relief, the frequency can be increased (eg, up to 20 minutes per hour). </p><p class="headingAnchor" id="H430557346"><span class="h3">Cytotoxic drugs</span><span class="headingEndMark"> — </span>Topical application of cold is recommended for extravasation of most cytotoxic vesicant or irritant drugs, <strong>except for</strong> the vinca alkaloids (<a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>), epipodophyllotoxins such as <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and possibly taxanes. The efficacy of cold application was suggested in a series of 175 patients with extravasation of a variety of chemotherapeutic agents, in which close to 90 percent of those treated with cold alone (15 minutes four times daily for three days) required no further therapy [<a href="#rid64">64</a>].</p><p>For extravasation of vinca alkaloids or epipodophyllotoxins, application of <strong>cold is contraindicated</strong>, as cold worsens the skin ulceration caused by these drugs, at least in animal models [<a href="#rid61">61,65</a>]. Cold opposes the action of <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> and is contraindicated in this setting. Heat is generally recommended for these agents, although most of the available data are derived from animal studies rather than clinical reports. Local heating is thought to result in localized vasodilation and increased blood flow, thereby enhancing the early, distributive phase of drug removal [<a href="#rid65">65</a>]. </p><p>For taxanes, the choice between cold or heat is less clear. Early guidelines suggested application of cold [<a href="#rid37">37</a>], although EONS/European Society for Medical Oncology (ESMO) guidelines suggest application of heat in this setting because the taxanes, similar to the vinca alkaloids, are non-DNA-binding agents and the general strategy for these types of extravasations is to dilute and diffuse [<a href="#rid24">24</a>]. Aside from extravasation recall phenomena, the long-term effects of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> extravasation are minimal and usually entail mild fibrosis around the extravasation site. However, skin toxicity, including desquamation following accidental extravasation, is more frequent with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> than paclitaxel, although serious long-term sequelae have not been described. The relative benefit of topical cooling for docetaxel extravasations is less clear than for paclitaxel; some (including the EONS) suggest that heat rather than cold be applied in such cases [<a href="#rid24">24,66</a>]. </p><p class="headingAnchor" id="H3275888248"><span class="h3">Noncytotoxic drugs</span><span class="headingEndMark"> — </span>For noncytotoxic agents, suggestions for application of cold or heat vary depending on the mechanism of potential injury and the use of antidotes [<a href="#rid7">7-9</a>]. (See <a class="local">'Selective use of antidotes'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acidic</strong> – For most acidic extravasations, cold compresses are appropriate with the exception of <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, for which the selection of cold or warm depends upon whether <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> is administered  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkaline</strong> – For most alkaline extravasations, cold compresses are appropriate with the exception of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, for which the selection of cold or warm depend upon whether <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> is administered  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperosmotic</strong> – For most hyperosmotic extravasations, warm compresses are used if <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> is administered, and cold compresses can be used if an antidote is not administered  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasopressor</strong> – For most vasopressor extravasation causing vasoconstriction, warm compresses are used, often in combination with vasodilator therapy  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p></p><p class="headingAnchor" id="H2950727018"><span class="h2">Selective use of antidotes</span><span class="headingEndMark"> — </span>Antidotes include <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> (anthracyclines), <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (alkylating agents), <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> (vinca alkaloids, taxanes), <a class="drug drug_general" data-topicid="8898" href="/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a> (DMSO) anthracyclines for cytotoxic extravasation and vasodilators and hyaluronidase for noncytotoxic agents. For some drugs (eg, <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a> [<a href="#rid67">67</a>]), there are no specific published antidotes [<a href="#rid68">68</a>]. (See <a class="local">'Cytotoxic agents'</a> below and <a class="local">'Noncytotoxic agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral intravenous device extravasation</strong> – Following extravasation from peripheral venous devices, specific antidotes have been suggested to prevent necrosis and ulceration, although none of these has been validated in randomized clinical trials  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central venous device extravasation</strong> – For extravasation of cytotoxic agents from a CVAD, intravenous <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> is more established as an antidote for anthracycline extravasation. However, the utility of other local antidotes (<a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a>, <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a>) is unclear, and their use is not recommended in guidelines from the EONS [<a href="#rid24">24</a>]. </p><p></p><p class="headingAnchor" id="H2935609376"><span class="h3">Dexrazoxane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">Dexrazoxane</a> is believed to chelate intracellular iron, block iron-assisted oxidative radical production, and inhibit the topoisomerase II beta isoenzyme, which has been implicated in anthracycline cardiotoxicity (See <a class="local">'Anthracyclines'</a> below and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.) </p><p class="headingAnchor" id="H4064801573"><span class="h3">Sodium thiosulfate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> creates an alkaline-rich site to which alkylating agents bind instead of to the tissue [<a href="#rid69">69</a>]. Local injection of sodium thiosulfate is used for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> extravasations as well as large volume injections or concentrated <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>) [<a href="#rid70">70,71</a>]. (See <a class="local">'Alkylating agents'</a> below.)</p><p><a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> infusion may also be beneficial for severe forms of cutaneous calcinosis related to <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> extravasation  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>) [<a href="#rid72">72</a>]. (See <a class="local">'Hyperosmotic, acidic, or alkaline agents'</a> below.)</p><p class="headingAnchor" id="H184105632"><span class="h3">Hyaluronidase</span><span class="headingEndMark"> — </span>The proteolytic enzyme <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> promotes the diffusion of subcutaneously injected solutions by hydrolyzing hyaluronic acid, one of the chief ingredients of connective tissue stroma. It is postulated that this creates a wider surface for dilution and aspiration of the drug [<a href="#rid73">73,74</a>]. Warmth is often used in conjunction with hyaluronidase to facilitate its mechanism of action. (See <a class="local">'Application of cold or heat'</a> above.)</p><p><a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">Hyaluronidase</a> may be useful for extravasation of cytotoxic  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>) or noncytotoxic  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>) agents. Local injection of hyaluronidase for extravasations of vinca alkaloids, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, epipodophyllotoxins, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, sodium chloride, calcium solutions, dextrose, and <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>. (See <a class="local">'Vinca alkaloids and taxanes'</a> below.)</p><p class="headingAnchor" id="H169768114"><span class="h3">Dimethyl sulfoxide</span><span class="headingEndMark"> — </span>DMSO has activity as a free radical scavenger, and at least some data support the view that tissue damage from vesicants (particularly anthracyclines) is caused by the formation of hydroxyl free radicals [<a href="#rid75">75,76</a>]. Topical application of DMSO can be used for anthracycline extravasation when <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> is not immediately available. A single, subcutaneous, local injection of DMSO is used for <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> extravasation, followed by topical application. The mechanism underlying a potential benefit from DMSO is uncertain. (See <a class="local">'Anthracyclines'</a> below.)</p><p class="headingAnchor" id="H2401242562"><span class="h3">Vasodilators</span><span class="headingEndMark"> — </span>For vasoactive drugs, <a class="drug drug_general" data-topicid="9767" href="/d/drug information/9767.html" rel="external">phentolamine</a> (eg, for <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> extravasation), or <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> (eg, for dopamine, epinephrine, <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>, <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> extravasation) can be administered. (See <a class="local">'Vasoactive drugs'</a> below.)</p><p class="headingAnchor" id="H2750766120"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are presumed to reduce local inflammation, but it has never been shown that tissue damage from vesicant extravasation is the result of an inflammatory process. In general, glucocorticoids are not indicated in the management of vesicant extravasations, except for large-volume extravasations of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (see <a class="local">'Alkylating agents'</a> below). This position is consistent with recommendations from the ONS and EONS for most cytotoxic drug extravasations [<a href="#rid24">24</a>]. Glucocorticoids may worsen the skin damage from <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> or vinca alkaloids, and they are specifically contraindicated in these situations.</p><p class="headingAnchor" id="H3963512883"><span class="h1">LOCAL TREATMENT OF SELECTED EXTRAVASATIONS</span><span class="headingEndMark"> — </span>Information regarding treatment for extravasation is largely based on animal models, anecdotal case reports, and a limited number of small uncontrolled studies [<a href="#rid8">8,77</a>]. No clinical trials have been performed to establish the role of specific interventions in the management of extravasation injury [<a href="#rid77">77,78</a>]. Furthermore, evaluation of the available published data on treatment of extravasation injury in humans is difficult owing to the variability in methods and treatment endpoints, and the confounding influence of nonpharmacologic therapy (ie, the application of cold or heat).</p><p>For extravasation from cytotoxic agents, guidelines for management are available from the Oncology Nursing Society (ONS) and European Oncology Nursing Society (EONS) [<a href="#rid24">24</a>]. The ONS standards were initially developed in 2009 [<a href="#rid79">79</a>], and were reiterated in 2011 and 2013 with little, if any, change [<a href="#rid80">80,81</a>]. With the use of standardized protocols, most extravasations are able to be managed conservatively with a reduced need for surgical intervention [<a href="#rid82">82</a>]. </p><p>Our recommendations are based on case descriptions, experience at some leading centers, or extrapolated according to mechanism of injury  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). Consult local protocols if available. Antidotes are used as potential adjuncts to initial care of extravasation injury. (See <a class="local">'Initial measures'</a> above.)</p><p class="headingAnchor" id="H1903861844"><span class="h2">Cytotoxic agents</span></p><p class="headingAnchor" id="H545989045"><span class="h3">Anthracyclines</span><span class="headingEndMark"> — </span>For extravasations of nonliposomal anthracyclines (<a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>), which have a high likelihood of producing tissue ulceration, in addition to cold therapy, we administer <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> as the initial treatment  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>). Treatment should be started as soon as possible, ideally within the first six hours after extravasation. <a class="drug drug_general" data-topicid="8898" href="/d/drug information/8898.html" rel="external">Dimethyl sulfoxide</a> (DMSO) (where available) represents an acceptable alternative to dexrazoxane if dexrazoxane is unavailable or cannot be started within six hours of the actual extravasation event. Studies of dexrazoxane demonstrate a slightly better efficacy compared with DMSO for anthracycline extravasations [<a href="#rid83">83</a>]. There is no evidence that combined use of dexrazoxane and topical DMSO provides any additional benefit. (See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p>Liposomal anthracycline formulations are generally not associated with necrotic injury, and treatment with <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> is generally not indicated; application of cold alone to reduce local inflammation (and avoidance of DMSO) is usually sufficient [<a href="#rid84">84-86</a>]. However, for the rare patient who develops symptomatic extravasation of <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, dexrazoxane may be useful [<a href="#rid87">87,88</a>]. </p><p>A benefit for <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> after anthracycline extravasation was initially suggested in animal studies and isolated case reports [<a href="#rid89">89-92</a>]. Dexrazoxane was subsequently evaluated in a review that included two multicenter studies involving patients with presumed anthracycline extravasations [<a href="#rid93">93</a>]. Dexrazoxane was administered intravenously as three one- to two-hour infusions through a different venous access location, with the first dose given within six hours of the actual extravasation and subsequent doses administered 24 and 48 hours after extravasation. The first and second doses were 1000 mg/m<sup>2</sup>, and the third dose was 500 mg/m<sup>2</sup>, up to maximum total doses of 2000, 2000, and 1000 mg, respectively. Extravasation was confirmed by fluorescence microscopy of a biopsy specimen in 54 cases. Only one patient (2 percent) who received therapy within six hours after the event required surgical debridement. The most frequent sequelae of the extravasations were mild pain and sensory disturbances (19 and 17 percent, respectively). Chemotherapy was able to be continued without interruption in 71 percent of cases.</p><p>The evidence supporting the use of DMSO comes from two observational studies in patients with chemotherapy extravasations, both of which used topical administration [<a href="#rid94">94,95</a>]. However, these studies used a DMSO concentration of &gt;90 percent, which is not available in the United States. The only available preparation is a 50 percent solution, which is marketed for intravesical use. </p><p class="bulletIndent1"><span class="glyph">●</span>In the largest series, 144 patients with chemotherapy extravasation of a variety of drugs received topical DMSO (application of a 99 percent solution every eight hours for seven days) plus local cooling therapy (60 minutes every eight hours for three days) [<a href="#rid94">94</a>]. The authors reported complete recovery within one week in 103 patients (71 percent), whereas 22 others recovered with more prolonged DMSO therapy (total success rate 87 percent). Ulceration developed in a sole patient with <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> extravasation. Interpretation of these results is difficult because of the combined use of both DMSO and topical cooling. Furthermore, only 62 extravasations were due to known vesicants (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, epirubicin), while the remainder involved irritant rather than vesicant drugs (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for DMSO independent of cold application in patients with anthracycline extravasation was suggested in a prospective series in which 0 of 20 patients who received topical DMSO (99 percent solution every six hours for 14 days) developed ulceration or required surgical management [<a href="#rid95">95</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">Dexrazoxane</a> has been approved by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for the treatment of anthracycline extravasation injury  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>). Guidelines from the ONS do not include DMSO, and even the manufacturer's package labeling information fails to recommend its use for anthracycline extravasations. DMSO was also not included in the recommended treatments for extravasation in 2012 guidelines from European Society for Medical Oncology (ESMO) and EONS [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H10"><span class="h3">Alkylating agents</span><span class="headingEndMark"> — </span>For large volume extravasation or concentrated <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, in addition to cold therapy, we inject <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> directly into the extravasation site  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a>) [<a href="#rid70">70,71</a>]. </p><p>The recommendation for thiosulfate for the treatment of extravasation of alkylating agents is based largely on in vitro data demonstrating an interaction of thiosulfate and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid96">96-100</a>]. <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> has also been suggested for extravasations of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> (a mechlorethamine derivative that usually acts as an irritant but can cause local tissue injury if extravasated) [<a href="#rid20">20</a>]. However, neither the ONS nor EONS has addressed the issue of sodium thiosulfate with this drug [<a href="#rid24">24</a>]. </p><p>The clinical efficacy of <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> in patients with extravasation of other agents was suggested in a series of 63 patients who had received <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, or <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> [<a href="#rid71">71</a>]. One-half were treated with <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> alone, whereas the remainder also received sodium thiosulfate (2 percent solution injected subcutaneously). No patient in either group developed skin ulceration or required surgery. The mean healing time for the group receiving thiosulfate was one-half that of the other group, although the lack of randomization in treatment assignment rendered this result inconclusive.</p><p>In addition, oral glucocorticoids may be of benefit in patients who have extravasated large amounts of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. In one series of five patients, the early administration of high-dose oral <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (8 mg twice daily for up to 14 days) appeared to have a beneficial effect on the severity and clinical course of the inflammatory reaction [<a href="#rid36">36</a>].</p><p>For <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, a freshly prepared 4 (1/6 Molar) or 2 percent solution of <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (2 mL for each mg thought to be extravasated) is recommended [<a href="#rid70">70,71</a>]. The solution is injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle. To make a 4 percent solution:</p><p class="bulletIndent1"><span class="glyph">●</span>If using 10 percent <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a>, mix 4 mL with 6 mL of sterile water for injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If using 25 percent <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a>, mix 1.6 mL with 8.4 mL of sterile water for injection. </p><p></p><p class="headingAnchor" id="H11"><span class="h3">Vinca alkaloids and taxanes</span><span class="headingEndMark"> — </span>For extravasation of the vinca alkaloids (<a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>) or taxanes (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>), in addition to heat, we inject <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> directly into the extravasation site. While the EONS suggests the use of hyaluronidase for extravasations these agents [<a href="#rid24">24</a>], guidelines from the ONS recommend hyaluronidase only for extravasations of vinca alkaloids, not other agents.</p><p>The evidence supporting the use of local infiltration with <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> is based on small series and case reports [<a href="#rid24">24,37,101</a>]. In one published study of six patients with extravasation of a vinca alkaloid (<a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>), pain resolved within several days of the extravasation in all six without the application of cold compresses [<a href="#rid101">101</a>]. A review of reports of treatment of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> extravasation found inconsistent results with hyaluronidase [<a href="#rid37">37</a>]. In a series of four cases (two managed with cold compresses with hyaluronidase injections around the extravasated area, and two treated with cold compresses alone), the use of hyaluronidase was associated with delayed healing. In contrast, in another small series, there was a complete disappearance of local symptoms (pain, erythema, swelling) with the use of hyaluronidase for a paclitaxel extravasation in five patients.</p><p><a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">Hyaluronidase</a> is administered as multiple subcutaneous injections around the affected area. Hyaluronidase should be administered within one hour of extravasation; some benefit may be derived if hyaluronidase is used within 12 hours. When hyaluronidase is used (all indications), avoid cold compresses as they oppose its action; warm compresses may be used. </p><p>Commercial preparations of <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> are available, but these have not been approved for this indication (ie, off-label use). The recommended dose is 1 mL (150 units) infiltrated subcutaneously, as five separate injections of 0.2 mL each, into the extravasated site along the leading edge of erythema using a separate 25 gauge or smaller needles. </p><p class="headingAnchor" id="H947740710"><span class="h2">Noncytotoxic agents</span><span class="headingEndMark"> — </span>The optimal approach to local therapy for extravasation of noncytotoxic vesicants is unclear, and there are no guidelines. The information provided in the table  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>), which is based on case descriptions, experience at some leading centers, or extrapolated according to mechanism of injury, can help guide management. </p><p class="headingAnchor" id="H4116611678"><span class="h3">Vasoactive drugs</span><span class="headingEndMark"> — </span>Vasodilators may be helpful for counteracting the vasoconstrictive effects of some noncytotoxic vasoconstrictive agents by helping to limit local ischemia that can lead to tissue necrosis  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9767" href="/d/drug information/9767.html" rel="external">Phentolamine</a> – Phentolamine is the preferred agent for most extravasations of vasopressor agents. Phentolamine antagonizes alpha-adrenergic receptors that are stimulated by catecholamine extravasation [<a href="#rid56">56,102-104</a>]. Phentolamine is administered as multiple subcutaneous injections around the affected area. It should be administered as soon as possible; greater benefit may be derived if it is used within 12 hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a><strong>/</strong><a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> – For <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> extravasation, topical nitroglycerin ointment and/or terbutaline administered subcutaneously may be considered. These agents are an alternative for vasopressor extravasation if <a class="drug drug_general" data-topicid="9767" href="/d/drug information/9767.html" rel="external">phentolamine</a> is not available [<a href="#rid105">105</a>]. Topical nitroglycerin 2% is applied as a 1-inch (2.5 cm) strip over affected area. It should be applied within one hour of extravasation. Avoid warm compresses when topical nitroglycerin is used. </p><p></p><p class="headingAnchor" id="H3692473090"><span class="h3">Hyperosmotic, acidic, or alkaline agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">Hyaluronidase</a> may be useful for treating predominantly hyperosmolar noncytotoxic extravasations, but also some acidic (eg, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>) or alkaline (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>) extravasations  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>).</p><p>Case reports also support potential benefit of <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> with extravasations of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid106">106</a>], <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a> [<a href="#rid107">107</a>], and other compounds, such as <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, high concentrations of dextrose [<a href="#rid101">101,108-111</a>], and extravasation of radiocontrast media [<a href="#rid112">112-114</a>].</p><p>For severe calcinosis, a thiosulfate infusion is administered once weekly for three weeks [<a href="#rid72">72</a>]. Intravenous <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> administration can be associated with anion gap acidosis more typically associated with patients who have chronic kidney disease [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/d/html/100751.html" rel="external">"Calcinosis cutis: Management", section on 'Topical or intralesional sodium thiosulfate'</a>.)</p><p class="headingAnchor" id="H3886501120"><span class="h1">CATHETER MANAGEMENT</span><span class="headingEndMark"> — </span>The management of the catheter largely depends on the device location, severity of extravasation, and for central venous access devices (CVADs), the cause. All patient factors, the events leading up to the extravasation, and the ongoing need for peripheral or central venous access should be assessed. When ongoing venous access is required, replacement should be well away from the site of extravasation. Alternative venous sites can be chosen using ultrasound guidance. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral intravenous catheters</strong> – Following the administration of any antidotes or <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigation for the early treatment of extravasation, <strong>all</strong> peripheral intravenous catheters should be removed. New intravenous access will need to be established at a site away from the injury often in the contralateral extremity. Central venous access may be preferred for the new access following a peripheral extravasation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CVADs</strong> – In addition to managing the local effects of the extravasated fluid, the CVADs needs to be addressed. Central venous catheter malfunction may be the cause of the extravasation injury, which can be related to a catheter that has disconnected (eg, port separated from catheter), has become malpositioned such that one of the infusion holes is no longer intravascular, or has perforated the vessel such that the tip of the catheter no longer resides in a vessel. (See  <a class="medical medical_review" href="/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a>.)</p><p></p><p class="bulletIndent1">For central venous catheters associated with vascular perforation, surgical consultation is appropriate. The catheter should be removed, and the site should be evaluated for bleeding. Endovascular or open surgical management may be required depending on the site of the vascular injury. (See  <a class="medical medical_review" href="/d/html/15195.html" rel="external">"Vascular complications of central venous access and their management in adults"</a>.)</p><p></p><p class="bulletIndent1">Whether to remove a CVAD depends on the extent of extravasation and the severity of symptoms: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a catheter malfunction was identified, symptoms related to extravasation are minimal, and alternative CVAD sites are limited, the CVAD can be evaluated for repair or replacement at the same site. Once the symptoms are resolved, use of the CVAD can be resumed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, if symptoms or signs are more serious (eg, severe or persistent pain, exposure of the catheter or port device, blistering or tissue ischemia), the CVAD should be removed, usually during the initial washout or debridement procedure. If ongoing central venous access is needed, it should be placed away from the site of extravasation. Temporary central venous access will be needed until any catheter-related infection has resolved. (See <a class="local">'Local tissue injury'</a> below.)</p><p></p><p class="headingAnchor" id="H3037063332"><span class="h1">SURGICAL MANAGEMENT</span><span class="headingEndMark"> — </span>Surgical consultation and intervention may be necessary to help limit and manage tissue necrosis and provide coverage in the event of tissue loss. Data regarding surgical intervention for extravasation injury from central venous access devices (CVADs) are limited to case reports and case series [<a href="#rid25">25,39,116-120</a>]. In one review, 27 of 545 patients (5 percent) required escharectomy, skin graft, or flap (regional or free) reconstruction [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H3162181833"><span class="h2">Surgical referral</span><span class="headingEndMark"> — </span>Although conservative management resolves many extravasation injuries without the need for surgical intervention, early referral (eg, general surgery, thoracic surgery, vascular surgery, plastic surgery) is important for facilitating planning, particularly under the following circumstances (see <a class="local">'Treatment overview'</a> above and <a class="local">'Surgical management'</a> above) [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Significant subcutaneous extravasation leading to skin compromise (erythema, eschar) or with a collection exerting a mass effect (skin ischemia, vascular compression).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extravasation into the chest (eg, pleural cavity, mediastinum).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central venous catheter malfunction (disconnect, migration, perforation).</p><p></p><p class="headingAnchor" id="H381598137"><span class="h2">Local tissue injury</span><span class="headingEndMark"> — </span>If tissue necrosis develops, the injury should be dressed with a nonadherent dressing (eg, petrolatum-based [Xeroform], semipermeable [Adaptic]) while the extent of tissue death demarcates [<a href="#rid121">121</a>]. The nonadherent dressing provides a moist, clean environment for healing and should be changed daily. Although wet-to-dry dressings can be considered to debride any open wounds, they are often painful for the patient and may induce bleeding with dressing changes. (See  <a class="medical medical_review" href="/d/html/15912.html" rel="external">"Basic principles of wound management", section on 'Wound dressings'</a>.)</p><p>Indications for surgical exploration include development of site infection or abscess, progression of the radiographic abnormalities concurrent with clinical deterioration, or clinical deterioration (tissue necrosis). Surgical debridement is also recommended for failure of response to general care measures with unresolved local tissue injury (ischemia, necrosis) [<a href="#rid24">24</a>]. Whether local surgical intervention is necessary in a patient complaining of persistent pain in the presence of normal-looking skin is unclear. </p><p>Full-thickness tissue necrosis and nonhealing skin ulcers resulting from an extravasation injury require debridement and skin closure, which may require skin grafting or flap coverage. However, the optimal timing of surgical intervention is controversial. Although some clinicians suggest early surgical intervention to prevent ulceration [<a href="#rid47">47,122</a>], a conservative approach is more often recommended [<a href="#rid123">123-128</a>], particularly because fewer than one-third of vesicant extravasations ultimately result in ulceration. Failure of initial conservative management with continued erythema, swelling and pain, or the presence of large areas of tissue necrosis or skin ulceration is an indication for surgery [<a href="#rid123">123,129</a>]. Some agents (eg, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>) are autofluorescent, a characteristic can be used to define the extent of extravasation [<a href="#rid130">130,131</a>]. In one small study, with the removal of all fluorescing tissue, no subsequent tissue necrosis occurred [<a href="#rid130">130</a>]. </p><p>Deep partial-thickness (wounds extending through the epidermis and into the deep dermis) or full-thickness (wounds extending through the entire dermis) skin defects that cannot be closed primarily can be managed with split- or full-thickness skin grafts, depending on the area of the body that is involved and the defect size. Larger defects typically require split-thickness skin grafts given the paucity of full-thickness skin graft donor sites. Full-thickness grafts, which have less contracture and greater thickness, may be preferred if they are available, for highly important functional and aesthetic areas of the body at sites. Graft take may be poor in areas of extravasation if debridement is incomplete and a healthy, vascularized wound base is not present. The principles of skin grafting are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15118.html" rel="external">"Skin autografting"</a>.)</p><p>Deeper injuries that have exposed the underlying tendons or bones require closure with a well-vascularized tissue flap, as a skin graft will not take on these poorly vascularized tissues. Local, regional, or distant free flaps can be used. Local options may be limited due to tissue damage from the extravasation, which can compromise the local blood supply and cause fibrosis of the surrounding tissue. Flaps bring their own blood to the area of reconstruction and can improve the vascularity of the damaged area. Prior to performing a free flap, an arteriogram is recommended to ensure that the recipient blood vessels near the site of the extravasation are patent and available for use. (See  <a class="medical medical_review" href="/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a>.)</p><p class="headingAnchor" id="H1419674114"><span class="h2">Mediastinal extravasation</span><span class="headingEndMark"> — </span>Depending on the area of involvement and the agent, mediastinoscopy or thoracoscopy can be used to assess the severity of the extravasation and the potential need for surgical debridement (eg, video-assisted thoracoscopic surgery [VATS], open thoracotomy if VATS is not possible), but this is uncommonly needed [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/15141.html" rel="external">"Overview of minimally invasive thoracic surgery"</a>.)</p><p>Outcomes following thoracic extravasation are overall very good; complications and long-term thoracic sequelae are rare. </p><p class="headingAnchor" id="H916212699"><span class="h2">Compartment syndrome</span><span class="headingEndMark"> — </span>While most extravasations occur superficial to the fascial compartments, compartment syndrome has been reported to occur (eg, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, high-pressure injection) [<a href="#rid132">132-134</a>]. The patient should be monitored for this complication, particularly for extravasations that occur in the hand. When compartment syndrome is identified, fasciotomy is used to treat compartment syndrome. (See  <a class="medical medical_review" href="/d/html/116596.html" rel="external">"Pathophysiology, classification, and causes of acute extremity compartment syndrome", section on 'Extravasation injury'</a> and  <a class="medical medical_review" href="/d/html/358.html" rel="external">"Acute compartment syndrome of the extremities"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for extravasation injury</strong> – The main risk factors for extravasation injury are improper catheter type or site selection for the type of pharmacologic agent/fluid being administered, and improper infusion technique. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – If extravasation of a vesicant agent is suspected, initial management should focus on minimizing the extent of drug extravasation (see <a class="local">'Treatment overview'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stop the infusion immediately. Do not flush the line and avoid applying pressure to the extravasated site.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevate the affected extremity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Do <strong>not</strong> remove the catheter/needle immediately. Rather, it should be left in place to aspirate fluid from the extravasated area to the extent that is possible and to facilitate the administration of an antidote to the local area  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>), if appropriate. (See <a class="local">'Selective use of antidotes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If an antidote will not be injected into the extravasation site, the catheter/needle can be removed after attempted aspiration of the subcutaneous tissues.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If appropriate and available, once an antidote has been administered, the peripheral intravenous catheter should be removed and replaced, as needed, at a site remote from the site of extravasation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most extravasations of vesicant agents other than the vinca alkaloids and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, we use the thermal therapy listed in the tables  (<a class="graphic graphic_table graphicRef67155" href="/d/graphic/67155.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>). (See <a class="local">'Application of cold or heat'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoid therapy is generally <strong>not</strong> indicated in the management of vesicant extravasation for most patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local treatment of specific extravasations</strong> – We use the following antidotes, when available, rather than no antidote to lessen the local tissue effects of the extravasation. (See <a class="local">'Local treatment of selected extravasations'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthracyclines</strong> – For extravasation of nonliposomal anthracyclines, we suggest systemic administration of <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical <a class="drug drug_general" data-topicid="8898" href="/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a> (DMSO) is an alternative if dexrazoxane is unavailable or cannot be started within six hours of the actual extravasation event. Liposomal anthracyclines are generally not associated with necrotic injury, and treatment with dexrazoxane is generally not indicated. (See <a class="local">'Anthracyclines'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alkylating agents</strong> – For large volume extravasation or concentrated <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, we suggest <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> injected directly into the extravasation site (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">For extravasation of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, we suggest administration of high doses of oral glucocorticoids (<a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg twice daily for up to 14 days) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Alkylating agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vinca alkaloids and taxanes</strong> – For extravasation of the vinca alkaloids (<a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>) and taxanes (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>), we suggest local injection of <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Vinca alkaloids and taxanes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noncytotoxic vesicants</strong> – The optimal approach to local therapy for extravasation of noncytotoxic vesicants is unclear, and there are no guidelines. The information provided in the table  (<a class="graphic graphic_table graphicRef127371" href="/d/graphic/127371.html" rel="external">table 2</a>), which is based on case descriptions, experience at some leading centers, or extrapolated according to mechanism of injury, can help guide management. (See <a class="local">'Noncytotoxic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central venous access-related extravasation</strong> – For patients with suspected extravasation from a central venous access device (CVAD), once the infusion is stopped, a chest radiograph should be obtained to evaluate the position of the catheter tip and the integrity of the catheter and any connections between components (eg, port device). The extent of extravasation can be evaluated with cross-sectional imaging, typically CT of the chest (jugular, subclavian venous access) or abdomen/pelvis (femoral venous access). Conservative management of chest extravasations is usually sufficient, but drainage or more extensive procedures may be necessary. Removal or retention of the CVAD depends upon the extent of extravasation and the severity of symptoms. (See <a class="local">'Catheter management'</a> above and <a class="local">'Mediastinal extravasation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – There are no uniform guidelines for the surgical treatment of extravasation injuries. General care follows the basic principles of wound management. Indications for surgical exploration include development of infection, progression of the radiographic abnormalities concurrent with clinical deterioration, or clinical deterioration (tissue necrosis). Surgical debridement is also recommended for inadequate response to general care measures with unresolved local tissue injury (ischemia, necrosis). (See <a class="local">'Surgical referral'</a> above and <a class="local">'Surgical management'</a> above.)</p><p></p><p class="headingAnchor" id="H3675137174"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Aimee S Payne, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hadaway L. Infiltration and extravasation. Am J Nurs 2007; 107:64.</a></li><li><a class="nounderline abstract_t">Dougherty L. IV therapy: recognizing the differences between infiltration and extravasation. Br J Nurs 2008; 17:896, 898.</a></li><li><a class="nounderline abstract_t">Tewfik G. Under-Reporting of a Critical Perioperative Adverse Event: Intravenous Infiltration and Extravasation. Drug Healthc Patient Saf 2020; 12:217.</a></li><li><a class="nounderline abstract_t">Marsh N, Webster J, Ullman AJ, et al. Peripheral intravenous catheter non-infectious complications in adults: A systematic review and meta-analysis. J Adv Nurs 2020; 76:3346.</a></li><li><a class="nounderline abstract_t">Yildizeli B, Laçin T, Batirel HF, Yüksel M. Complications and management of long-term central venous access catheters and ports. J Vasc Access 2004; 5:174.</a></li><li><a class="nounderline abstract_t">Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016; 7:87.</a></li><li><a class="nounderline abstract_t">David V, Christou N, Etienne P, et al. Extravasation of Noncytotoxic Drugs. Ann Pharmacother 2020; 54:804.</a></li><li><a class="nounderline abstract_t">Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 2014; 34:617.</a></li><li><a class="nounderline abstract_t">Le A, Patel S. Extravasation of Noncytotoxic Drugs: A Review of the Literature. Ann Pharmacother 2014; 48:870.</a></li><li><a class="nounderline abstract_t">Alexander L. Extravasation Injuries: A Trivial Injury Often Overlooked with Disastrous Consequences. World J Plast Surg 2020; 9:326.</a></li><li><a class="nounderline abstract_t">Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002; 49:369.</a></li><li><a class="nounderline abstract_t">Hong S, Kim SH, Lee HK, et al. Extravasation of TPN following central venous catheter migration. Respir Med Case Rep 2022; 37:101623.</a></li><li><a class="nounderline abstract_t">Biffi R, Pozzi S, Agazzi A, et al. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 2004; 15:296.</a></li><li><a class="nounderline abstract_t">Narducci F, Jean-Laurent M, Boulanger L, et al. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. Eur J Surg Oncol 2011; 37:913.</a></li><li><a class="nounderline abstract_t">Quintanar Verdúguez T, Blanco Jarava A, Martínez-Barbeito MB, et al. Mediastinal extravasation of doxorubicin. Clin Transl Oncol 2008; 10:128.</a></li><li><a class="nounderline abstract_t">Roditi G, Khan N, van der Molen AJ, et al. Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines. Eur Radiol 2022; 32:3056.</a></li><li><a class="nounderline abstract_t">Doellman D, Hadaway L, Bowe-Geddes LA, et al. Infiltration and extravasation: update on prevention and management. J Infus Nurs 2009; 32:203.</a></li><li><a class="nounderline abstract_t">Gorski LA, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs 2021; 44:S1.</a></li><li><a class="nounderline abstract_t">Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006; 33:139.</a></li><li><a class="nounderline abstract_t">Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011; 27:82.</a></li><li><a class="nounderline abstract_t">Wengström Y, Margulies A, European Oncology Nursing Society Task Force. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs 2008; 12:357.</a></li><li><a class="nounderline abstract_t">Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006; 33:1134.</a></li><li><a class="nounderline abstract_t">Schulmeister L, Camp-Sorrell D. Chemotherapy extravasation from implanted ports. Oncol Nurs Forum 2000; 27:531.</a></li><li><a class="nounderline abstract_t">Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012; 23 Suppl 7:vii167.</a></li><li><a class="nounderline abstract_t">Bozkurt AK, Uzel B, Akman C, et al. Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol 2003; 26:121.</a></li><li><a class="nounderline abstract_t">Mandlik V, Prantl L, Schreyer AG. Contrast Media Extravasation in CT and MRI - A Literature Review and Strategies for Therapy. Rofo 2019; 191:25.</a></li><li><a class="nounderline abstract_t">Barrera CA, White AM, Shepherd AM, et al. Contrast Extravasation using Power Injectors for Contrast-Enhanced Computed Tomography in Children: Frequency and Injury Severity. Acad Radiol 2019; 26:1668.</a></li><li><a class="nounderline abstract_t">van Veelen NM, Link BC, Donner G, et al. Compartment syndrome of the forearm caused by contrast medium extravasation: A case report and review of the literature. Clin Imaging 2020; 61:58.</a></li><li><a class="nounderline abstract_t">Verykiou S, Aljefri K, Gopee H, et al. Cutaneous manifestations of phosphate solution extravasation. Clin Exp Dermatol 2018; 43:42.</a></li><li><a class="nounderline abstract_t">Kishi C, Amano H, Shimizu A, et al. Cutaneous necrosis induced by extravasation of hydroxyzine. Eur J Dermatol 2014; 24:131.</a></li><li><a class="nounderline abstract_t">Varacallo M, Shirey L, Kavuri V, Harding S. Acute compartment syndrome of the hand secondary to propofol extravasation. J Clin Anesth 2018; 47:1.</a></li><li><a class="nounderline abstract_t">Hannon MG, Lee SK. Extravasation injuries. J Hand Surg Am 2011; 36:2060.</a></li><li><a class="nounderline abstract_t">Goutos I, Cogswell LK, Giele H. Extravasation injuries: a review. J Hand Surg Eur Vol 2014; 39:808.</a></li><li><a class="nounderline abstract_t">Baur M, Kienzer HR, Rath T, Dittrich C. Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course. Onkologie 2000; 23:468.</a></li><li><a class="nounderline abstract_t">Foo KF, Michael M, Toner G, Zalcberg J. A case report of oxaliplatin extravasation. Ann Oncol 2003; 14:961.</a></li><li><a class="nounderline abstract_t">Kretzschmar A, Pink D, Thuss-Patience P, et al. Extravasations of oxaliplatin. J Clin Oncol 2003; 21:4068.</a></li><li><a class="nounderline abstract_t">Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11:270.</a></li><li><a class="nounderline abstract_t">Bicher A, Levenback C, Burke TW, et al. Infusion site soft-tissue injury after paclitaxel administration. Cancer 1995; 76:116.</a></li><li><a class="nounderline abstract_t">Barutca S, Kadikoylu G, Bolaman Z, et al. Extravasation of paclitaxel into breast tissue from central catheter port. Support Care Cancer 2002; 10:563.</a></li><li><a class="nounderline abstract_t">Ajani JA, Dodd LG, Daugherty K, et al. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 1994; 86:51.</a></li><li><a class="nounderline abstract_t">Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997; 17:163.</a></li><li class="breakAll">Schulmeister L. Extravasation. In: MASCC Textbook of Cancer Supportive Care and Cancer Survivorship, Olver IN (Ed), Springer, New York 2011. p.351.</li><li><a class="nounderline abstract_t">Luke E. Mitoxantrone-induced extravasation. Oncol Nurs Forum 2005; 32:27.</a></li><li><a class="nounderline abstract_t">Shafaee MN, Salahudeen AA, Valero V. Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. J Oncol Pract 2017; 13:555.</a></li><li class="breakAll">United States Prescribing Information for enfortumaab vedotin available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf (Accessed on December 19, 2019).</li><li><a class="nounderline abstract_t">Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</a></li><li><a class="nounderline abstract_t">Loth TS, Eversmann WW Jr. Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg Am 1986; 11:388.</a></li><li><a class="nounderline abstract_t">Shapiro J, Richardson GE. Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 1994; 12:2237.</a></li><li><a class="nounderline abstract_t">Meehan JL, Sporn JR. Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. J Natl Cancer Inst 1994; 86:1250.</a></li><li><a class="nounderline abstract_t">du Bois A, Kommoss FG, Pfisterer J, et al. Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 1996; 60:94.</a></li><li><a class="nounderline abstract_t">Kramer F, Schippert C, Rinnau F, et al. The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation. Ann Pharmacother 2011; 45:e11.</a></li><li><a class="nounderline abstract_t">Ley BD, Millán GG, Perez JS, et al. Docetaxel recall phenomenon at the site of previous drug extravasation. Arch Dermatol 2010; 146:1190.</a></li><li><a class="nounderline abstract_t">Valencak J, Troch M, Raderer M. Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy. J Natl Cancer Inst 2007; 99:177.</a></li><li><a class="nounderline abstract_t">Saini A, Berruti A, Sperone P, et al. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. Lancet Oncol 2006; 7:186.</a></li><li><a class="nounderline abstract_t">Wilson J, Carder P, Gooi J, Nishikawa H. Recall phenomenon following epirubicin. Clin Oncol (R Coll Radiol) 1999; 11:424.</a></li><li><a class="nounderline abstract_t">Tran QK, Mester G, Bzhilyanskaya V, et al. Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis. Am J Emerg Med 2020; 38:2434.</a></li><li><a class="nounderline abstract_t">Yucha CB, Hastings-Tolsma M, Szeverenyi NM. Effect of elevation on intravenous extravasations. J Intraven Nurs 1994; 17:231.</a></li><li><a class="nounderline abstract_t">Tom A, Joshi J, Golla MK, Lashkari HP. Doxorubicin Extravasation from a Port-a-cath into Pleural Space in a Young Girl: A Case Report and Review of Literature. J Indian Assoc Pediatr Surg 2022; 27:648.</a></li><li><a class="nounderline abstract_t">Chang R, Murray N. Management of anthracycline extravasation into the pleural space. Oxf Med Case Reports 2016; 2016:omw079.</a></li><li><a class="nounderline abstract_t">Rodier JM, Malbec L, Lauraine EP, et al. Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case. J Cancer Res Clin Oncol 1996; 122:566.</a></li><li><a class="nounderline abstract_t">Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12:245.</a></li><li><a class="nounderline abstract_t">Hastings-Tolsma MT, Yucha CB, Tompkins J, et al. Effect of warm and cold applications on the resolution of i.v. infiltrations. Res Nurs Health 1993; 16:171.</a></li><li><a class="nounderline abstract_t">Yucha CB, Hastings-Tolsma M, Szeverenyi NM. Differences among intravenous extravasations using four common solutions. J Intraven Nurs 1993; 16:277.</a></li><li><a class="nounderline abstract_t">Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985; 75:397.</a></li><li><a class="nounderline abstract_t">Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985; 74:113.</a></li><li><a class="nounderline abstract_t">Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45:438.</a></li><li><a class="nounderline abstract_t">Theman TA, Hartzell TL, Sinha I, et al. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2009; 27:e198.</a></li><li><a class="nounderline abstract_t">Jordan K, Jahn F, Jordan B, et al. Trabectedin: Supportive care strategies and safety profile. Crit Rev Oncol Hematol 2015; 94:279.</a></li><li><a class="nounderline abstract_t">Boschi R, Rostagno E. Extravasation of antineoplastic agents: prevention and treatments. Pediatr Rep 2012; 4:e28.</a></li><li><a class="nounderline abstract_t">Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27:347.</a></li><li><a class="nounderline abstract_t">Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992; 30:330.</a></li><li><a class="nounderline abstract_t">Lin CY, Hsieh KC, Yeh MC, et al. Skin necrosis after intravenous calcium chloride administration as a complication of parathyroidectomy for secondary hyperparathyroidism: report of four cases. Surg Today 2007; 37:778.</a></li><li><a class="nounderline abstract_t">Sharma DSC, Lahiri MA. Use of hyaluronidase in plastic surgery: A review. J Plast Reconstr Aesthet Surg 2021; 74:1610.</a></li><li><a class="nounderline abstract_t">Weber GC, Buhren BA, Schrumpf H, et al. Clinical Applications of Hyaluronidase. Adv Exp Med Biol 2019; 1148:255.</a></li><li><a class="nounderline abstract_t">Monstrey SJ, Mullick P, Narayanan K, Ramasastry SS. Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163.</a></li><li><a class="nounderline abstract_t">Averbuch SD, Boldt M, Gaudiano G, et al. Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. J Clin Invest 1988; 81:142.</a></li><li><a class="nounderline abstract_t">Harrold K, Gould D, Drey N. The management of cytotoxic chemotherapy extravasation: a systematic review of the literature to evaluate the evidence underpinning contemporary practice. Eur J Cancer Care (Engl) 2015; 24:771.</a></li><li><a class="nounderline abstract_t">Wickham R, Engelking C, Sauerland C, Corbi D. Vesicant extravasation part II: Evidence-based management and continuing controversies. Oncol Nurs Forum 2006; 33:1143.</a></li><li><a class="nounderline abstract_t">Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum 2009; 36:651.</a></li><li><a class="nounderline abstract_t">Jacobson JO, Polovich M, Gilmore TR, et al. Revisions to the 2009 american society of clinical oncology/oncology nursing society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract 2012; 8:2.</a></li><li><a class="nounderline abstract_t">Neuss MN, Polovich M, McNiff K, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncol Nurs Forum 2013; 40:225.</a></li><li><a class="nounderline abstract_t">Pluschnig U, Haslik W, Bayer G, et al. Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. Support Care Cancer 2015; 23:1741.</a></li><li><a class="nounderline abstract_t">Pérez-Fidalgo JA, Cervantes A. Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'. Ann Oncol 2013; 24:1129.</a></li><li><a class="nounderline abstract_t">Howell G, Oliai C, Schiller G. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review. Anticancer Res 2018; 38:6927.</a></li><li><a class="nounderline abstract_t">Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995; 87:1556.</a></li><li><a class="nounderline abstract_t">Curtit E, Chaigneau L, Pauchot J, et al. Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury. Anticancer Res 2012; 32:1481.</a></li><li><a class="nounderline abstract_t">Vos FY, Lesterhuis WJ, Brüggemann RJ, Graaf WT. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. Anticancer Drugs 2012; 23:139.</a></li><li><a class="nounderline abstract_t">Caballero Romero Á, Delgado Ureña MT, Salmerón García A, et al. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes. Anticancer Drugs 2018; 29:821.</a></li><li><a class="nounderline abstract_t">Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 2001; 12:405.</a></li><li><a class="nounderline abstract_t">Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg 2003; 37:174.</a></li><li><a class="nounderline abstract_t">Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000; 6:3680.</a></li><li><a class="nounderline abstract_t">Langer SW, Sehested M, Jensen PB, et al. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000; 18:3064.</a></li><li><a class="nounderline abstract_t">Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007; 18:546.</a></li><li><a class="nounderline abstract_t">Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13:2851.</a></li><li><a class="nounderline abstract_t">Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6:1732.</a></li><li><a class="nounderline abstract_t">BONADONNA G, KARNOFSKY DA. PROTECTION STUDIES WITH SODIUM THIOSULFATE AGAINST METHYL BIS (BETA-CHLOROETHYL)AMINE HYDROCHLORIDE (HN2) AND ITS ETHYLENIMONIUM DERIVATIVE. Clin Pharmacol Ther 1965; 6:50.</a></li><li><a class="nounderline abstract_t">LAWRENCE W Jr, TAYAO MS, MAHAJAN RD, et al. SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY. J Surg Res 1964; 4:483.</a></li><li><a class="nounderline abstract_t">Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemother Pharmacol 1988; 22:299.</a></li><li><a class="nounderline abstract_t">HATIBOGLU I, MIHICH E, MOORE GE, NICHOL CA. Use of sodium thiosulfate as a neutralizing agent during regional administration of nitrogen mustard: an experimental study. Ann Surg 1962; 156:994.</a></li><li><a class="nounderline abstract_t">Dorr RT, Alberts DS, Einspahr J, et al. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Cancer Treat Rep 1987; 71:267.</a></li><li><a class="nounderline abstract_t">Bertelli G, Dini D, Forno GB, et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 1994; 120:505.</a></li><li><a class="nounderline abstract_t">Plum M, Moukhachen O. Alternative Pharmacological Management of Vasopressor Extravasation in the Absence of Phentolamine. P T 2017; 42:581.</a></li><li><a class="nounderline abstract_t">Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. J Crit Care 2015; 30:653.e9.</a></li><li><a class="nounderline abstract_t">Maguire WM, Reisdorff EJ, Smith D, Wiegenstein JG. Epinephrine-induced vasospasm reversed by phentolamine digital block. Am J Emerg Med 1990; 8:46.</a></li><li><a class="nounderline abstract_t">Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. Plast Reconstr Surg 1989; 84:811.</a></li><li><a class="nounderline abstract_t">Sokol DK, Dahlmann A, Dunn DW. Hyaluronidase treatment for intravenous phenytoin extravasation. J Child Neurol 1998; 13:246.</a></li><li><a class="nounderline abstract_t">Zenk KE, Dungy CI, Greene GR. Nafcillin extravasation injury. Use of hyaluronidase as an antidote. Am J Dis Child 1981; 135:1113.</a></li><li><a class="nounderline abstract_t">Wiegand R, Brown J. Hyaluronidase for the management of dextrose extravasation. Am J Emerg Med 2010; 28:257.e1.</a></li><li><a class="nounderline abstract_t">Lawson SL, Brady W, Mahmoud A. Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment--a clinical report. Am J Emerg Med 2013; 31:886.e3.</a></li><li><a class="nounderline abstract_t">Cicchetti S, Jemec B, Gault DT. Two case reports of vinorelbine extravasation: management and review of the literature. Tumori 2000; 86:289.</a></li><li><a class="nounderline abstract_t">Kumar MM, Sprung J. The use of hyaluronidase to treat mannitol extravasation. Anesth Analg 2003; 97:1199.</a></li><li><a class="nounderline abstract_t">Heshmatzadeh Behzadi A, Farooq Z, Newhouse JH, Prince MR. MRI and CT contrast media extravasation: A systematic review. Medicine (Baltimore) 2018; 97:e0055.</a></li><li><a class="nounderline abstract_t">Cochran ST, Bomyea K, Kahn M. Treatment of iodinated contrast material extravasation with hyaluronidase. Acad Radiol 2002; 9 Suppl 2:S544.</a></li><li><a class="nounderline abstract_t">Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. Am J Emerg Med 2012; 30:2102.e1.</a></li><li><a class="nounderline abstract_t">Mao M, Lee S, Kashani K, et al. Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. J Med Toxicol 2013; 9:274.</a></li><li><a class="nounderline abstract_t">Fırat C, Erbatur S, Aytekin AH. Management of extravasation injuries: a retrospective study. J Plast Surg Hand Surg 2013; 47:60.</a></li><li><a class="nounderline abstract_t">Shenaq SM, Abbase EH, Friedman JD. Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am 1996; 5:825.</a></li><li><a class="nounderline abstract_t">Uges JW, Vollaard AM, Wilms EB, Brouwer RE. Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. Int J Clin Oncol 2006; 11:467.</a></li><li><a class="nounderline abstract_t">Haslik W, Hacker S, Felberbauer FX, et al. Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy. Eur J Surg Oncol 2015; 41:378.</a></li><li><a class="nounderline abstract_t">Onesti MG, Carella S, Fioramonti P, Scuderi N. Chemotherapy Extravasation Management: 21-Year Experience. Ann Plast Surg 2017; 79:450.</a></li><li><a class="nounderline abstract_t">Buchanan PJ, Kung TA, Cederna PS. Evidence-based medicine: Wound closure. Plast Reconstr Surg 2014; 134:1391.</a></li><li><a class="nounderline abstract_t">Heitmann C, Durmus C, Ingianni G. Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg Br 1998; 23:666.</a></li><li><a class="nounderline abstract_t">Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982; 49:1796.</a></li><li><a class="nounderline abstract_t">Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 1987; 5:1116.</a></li><li><a class="nounderline abstract_t">Cox K, Stuart-Harris R, Abdini G, et al. The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 1988; 148:185.</a></li><li><a class="nounderline abstract_t">Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995; 22:57.</a></li><li><a class="nounderline abstract_t">Scuderi N, Onesti MG. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 1994; 32:39.</a></li><li><a class="nounderline abstract_t">Heckler FR. Current thoughts on extravasation injuries. Clin Plast Surg 1989; 16:557.</a></li><li><a class="nounderline abstract_t">Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4:41.</a></li><li><a class="nounderline abstract_t">Dahlstrøm KK, Chenoufi HL, Daugaard S. Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. Experimental and clinical studies. Cancer 1990; 65:1722.</a></li><li><a class="nounderline abstract_t">Langer SW, Sehested M, Jensen PB. Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori 2009; 95:273.</a></li><li><a class="nounderline abstract_t">Edwards JJ, Samuels D, Fu ES. Forearm compartment syndrome from intravenous mannitol extravasation during general anesthesia. Anesth Analg 2003; 96:245.</a></li><li><a class="nounderline abstract_t">Erickson BA, Yap RL, Pazona JF, et al. Mannitol extravasation during partial nephrectomy leading to forearm compartment syndrome. Int Braz J Urol 2007; 33:68.</a></li><li><a class="nounderline abstract_t">Stahl S, Lerner A. Compartment syndrome of the forearm following extravasation of mannitol in an unconscious patient. Acta Neurochir (Wien) 2000; 142:945.</a></li></ol></div><div id="topicVersionRevision">Topic 2797 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667395" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infiltration and extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18935841" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : IV therapy: recognizing the differences between infiltration and extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33223853" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Under-Reporting of a Critical Perioperative Adverse Event: Intravenous Infiltration and Extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33016412" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Peripheral intravenous catheter non-infectious complications in adults: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16596562" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Complications and management of long-term central venous access catheters and ports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26862492" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Overview, prevention and management of chemotherapy extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054312" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Extravasation of Noncytotoxic Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24420913" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of extravasation injuries: a focused evaluation of noncytotoxic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714850" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Extravasation of Noncytotoxic Drugs: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33330011" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Extravasation Injuries: A Trivial Injury Often Overlooked with Disastrous Consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Retrospective study of the management of chemotherapeutic extravasation injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313559" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extravasation of TPN following central venous catheter migration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760125" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21831566" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258513" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mediastinal extravasation of doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175378" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605999" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infiltration and extravasation: update on prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33394637" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infusion Therapy Standards of Practice, 8th Edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473651" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extravasation of chemotherapeutic agents: prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255716" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Extravasation management: clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765210" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : European Oncology Nursing Society extravasation guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149396" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10785905" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chemotherapy extravasation from implanted ports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22997449" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714879" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intrathoracic extravasation of antineoplastic agents: case report and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29913522" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Contrast Media Extravasation in CT and MRI - A Literature Review and Strategies for Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31138458" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Contrast Extravasation using Power Injectors for Contrast-Enhanced Computed Tomography in Children: Frequency and Injury Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31978761" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Compartment syndrome of the forearm caused by contrast medium extravasation: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29082559" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cutaneous manifestations of phosphate solution extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508797" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cutaneous necrosis induced by extravasation of hydroxyzine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29476968" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute compartment syndrome of the hand secondary to propofol extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123049" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extravasation injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401738" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Extravasation injuries: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11441243" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796037" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A case report of oxaliplatin extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581435" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Extravasations of oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690542" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A review of clinical experience with paclitaxel extravasations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630862" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Infusion site soft-tissue injury after paclitaxel administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324812" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Extravasation of paclitaxel into breast tissue from central catheter port.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903699" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017777" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Severe necrosis due to paclitaxel extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017777" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe necrosis due to paclitaxel extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15682531" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mitoxantrone-induced extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678590" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678590" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071309" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mucocutaneous reactions to chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711613" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment methods for extravasations of chemotherapeutic agents: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7931497" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913725" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557235" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266630" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956672" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Docetaxel recall phenomenon at the site of previous drug extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17228004" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455484" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663338" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recall phenomenon following epirubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33039229" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965367" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of elevation on intravenous extravasations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36530827" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Doxorubicin Extravasation from a Port-a-cath into Pleural Space in a Young Girl: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699056" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of anthracycline extravasation into the pleural space.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781572" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646823" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevention and management of extravasation of cytotoxic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8497669" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of warm and cold applications on the resolution of i.v. infiltrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229429" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Differences among intravenous extravasations using four common solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883378" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : What is the appropriate management of tissue extravasation by antitumor agents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3855472" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037169" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805684" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794812" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Trabectedin: Supportive care strategies and safety profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25396033" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Extravasation of antineoplastic agents: prevention and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864222" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Systemic therapy emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1643703" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713732" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Skin necrosis after intravenous calcium chloride administration as a complication of parathyroidectomy for secondary hyperparathyroidism: report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34024740" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Use of hyaluronidase in plastic surgery: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31482503" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Applications of Hyaluronidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043586" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (Adriamycin) extravasation injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3121673" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26274490" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The management of cytotoxic chemotherapy extravasation: a systematic review of the literature to evaluate the evidence underpinning contemporary practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149397" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vesicant extravasation part II: Evidence-based management and continuing controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887353" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22548003" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Revisions to the 2009 american society of clinical oncology/oncology nursing society chemotherapy administration safety standards: expanding the scope to include inpatient settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619103" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25433440" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406727" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504411" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563191" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lack of vesicant injury following extravasation of liposomal doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22493389" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934601" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036190" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332155" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12841619" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999761" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of anthracycline extravasation with dexrazoxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944144" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Dexrazoxane in anthracycline extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185744" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595748" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183703" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14253284" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : PROTECTION STUDIES WITH SODIUM THIOSULFATE AGAINST METHYL BIS (BETA-CHLOROETHYL)AMINE HYDROCHLORIDE (HN2) AND ITS ETHYLENIMONIUM DERIVATIVE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14224011" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3168143" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13960951" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Use of sodium thiosulfate as a neutralizing agent during regional administration of nitrogen mustard: an experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3815394" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8207052" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28890646" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Alternative Pharmacological Management of Vasopressor Extravasation in the Absence of Phentolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25669592" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293835" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Epinephrine-induced vasospasm reversed by phentolamine digital block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2510208" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Reversal of dopamine extravasation injury with topical nitroglycerin ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620019" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hyaluronidase treatment for intravenous phenytoin extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315807" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nafcillin extravasation injury. Use of hyaluronidase as an antidote.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159411" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hyaluronidase for the management of dextrose extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602753" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment--a clinical report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11016706" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Two case reports of vinorelbine extravasation: management and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500188" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The use of hyaluronidase to treat mannitol extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29489663" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : MRI and CT contrast media extravasation: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12188333" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Treatment of iodinated contrast material extravasation with hyaluronidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633726" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Extravasation of contrast media managed with recombinant human hyaluronidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636659" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Severe anion gap acidosis associated with intravenous sodium thiosulfate administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190022" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Management of extravasation injuries: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8899947" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Soft-tissue reconstruction following extravasation of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17180516" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25515823" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28906302" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chemotherapy Extravasation Management: 21-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415102" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Evidence-based medicine: Wound closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9821616" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Surgical management after doxorubicin and epirubicin extravasation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7042076" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Treatment of tissue extravasation by antitumor agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3298560" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Etiology and treatment of chemotherapeutic agent extravasation injuries: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277019" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708525" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Vesicant extravasation: myths and realities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141535" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Antitumor agents: extravasation, management, and surgical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673635" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Current thoughts on extravasation injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182147" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Antidotes to vesicant chemotherapy extravasations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317755" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. Experimental and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19688963" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Anthracycline extravasation: a comprehensive review of experimental and clinical treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12505960" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Forearm compartment syndrome from intravenous mannitol extravasation during general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17335600" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Mannitol extravasation during partial nephrectomy leading to forearm compartment syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11086836" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Compartment syndrome of the forearm following extravasation of mannitol in an unconscious patient.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
